New hope for severe colitis: experimental drug BRS201 enters human trial
NCT ID NCT06420492
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new oral drug called BRS201 in 20 adults with severe ulcerative colitis who have not improved with standard treatments. Participants take the drug twice daily for 4 weeks and attend 8 clinic visits for blood, stool, and urine tests. The goal is to see if BRS201 can reduce inflammation and improve symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
NOT_YET_RECRUITINGChestnut Hill, Massachusetts, 02467, United States
-
Brigham and Women's Hospital
RECRUITINGChestnut Hill, Massachusetts, 02467, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a glass of pomegranate juice tame gut inflammation?